Woo-Hyun Lee (Chair)
Chairman of OCI Holdings, leading the corporate business management of OCI Group, a pioneer in the Korean chemical industry with over 60 years of history.
With his expertise in finance through vast experiences acquired from global financial companies, Mr. Lee has shown leadership in enhancing both the financial stability as well as the management system of OCI. He joined the company in 2005 as head of Planning and Strategy and served as a President/CEO from 2013. Mr. Lee has been at the helm of the polysilicon and solar energy businesses which has grown significantly under his leadership.
In 2018, Mr. Lee dived into biotech business as OCI´s new growth initiative, making strategic investments in ventures with cutting-edge bio technologies and high growth potential. In 2022, Mr. Lee led the acquisition of stake in Bukwang Pharmaceutical to lay the foundation for joint management, accelerating penetration into the pharmaceutical and bio sector. He was appointed as the new Vice Chairman of Bukwang Pharmaceutical in March 2022.
As the Chairman of OCI Holdings, he is contributing to enhance the value of the OCI Group by establishing an optimal investment strategy and laying a foundation for continued growth.
Jae Young Lee
Chief Strategic Officer of OCI Holdings from May 2023, oversees OCI Holdings’ investments, M&A activities, as well as the management of domestic and international subsidiaries, including Bukwang Pharmaceuticals.
He graduated from Seoul National University with a degree in Business Administration in 1999 and completed the LLM program at Columbia Law School in 2006. Prior to joining OCI Group, he worked as a public prosecutor for 17 years, accumulating experience in various economic and labor-related cases.
Leveraging his background as a lawyer, he has been responsible for OCI Group’s legal and audit functions since joining the group in 2019. He is also in charge of the establishment and management of compliance policies within the OCI Group.
Dr. Mahmoud Mahmoudian, FRS
Dr. Mahmoud Mahmoudian brings over 25 years of leadership in biotech innovation, fund raising, company building, and venture creation driving growth strategies to develop and commercialize novel medicines. He was recruited to Cobro Ventures as Partner operating across its portfolio as President, CEO, and Chief Business Officer. Prior to this position, he was Senior Vice President, Head of External Innovation Hub at Sumitomo Pharma establishing a corporate venture fund and developing strategic partnerships as an early-stage investor.
Earlier in his career, Dr. Mahmoudian led global drug development and innovation teams at Merck, GlaxoSmithKline and Ferring with 10 FDA approvals ($15B sales). Dr. Mahmoudian earned his Doctor and Master of Science in Biotechnology from the Imperial College London. He is on the Board of Directors of BioEclipse Therapeutics and Caravan Biologix, an Executive in Residence at Columbia and Princeton Universities, and a Fellow of the Royal Society (FRS). Dr. Mahmoudian joins Contera Pharma as an independent board member.
Dr. Sooyeon Park
Dr. Sooyeon Park, RPh, MBA, brings over 25 years of experience in clinical operations, regulatory strategy, and global team management, including leadership roles at GSK where she has earned extensive expertise in managing clinical programs and served in industry advisory committees. Currently employed at Bukwang Pharmaceutical, Sooyeon serves as an important link between Contera Pharma and its parent company and owners, leveraging her broad expertise to support Contera Pharma’s clinical and strategic objectives.
Paul E.G. Kristjansen
Dr. Paul E.G. Kristjansen, MD, PhD, and DMSc, brings decades of expertise in research, clinical development, and business strategy. With a background at the University of Copenhagen, Harvard University, Novo Nordisk, and Lundbeck A/S, Dr. Kristjansen has led R&D initiatives in oncology, autoimmunity, and neurological diseases, with specific focus on early-stage drug development and translational disease models. Dr. Kristjansen has authored more than 100 scientific papers, book chapters, reviews, and patents.
In his five years in business development at Lundbeck A/S, Dr. Kristjansen successfully directed in-licensing and M&A activities. Most recently, he joined The Lundbeck Foundation, where he as Senior Scientific Director manages the Frontiers Grants program to accelerate basic research toward biotech innovation. Dr. Paul E.G. Kristjansen acts as an independent board member.
The Lundbeck Foundation has no financial engagement in Contera Pharma.
Thomas Sager
CEO at Contera Pharma, has a Ph.D. in neuroscience and more than 24 years of drug discovery experience acquired in the biotech and pharma industry. For more than a decade he held various leadership roles in R&D drug discovery at Lundbeck A/S, covering both neurology and psychiatry, and has taken numerous projects through from discovery to development. His scientific work generated over 35 peer-reviewed papers. Over the years he served as invited reviewer for many organizations, including the Michael J. Fox Foundation.
In 2012, Thomas Sager joined Business Development at Lundbeck A/S, where he served as Vice President, Head of Business Development, Licensing and Scientific Assessment until November 2020, where he established the licensing strategy, was responsible for the execution of scientific assessments and was a project leader for corporate strategy initiatives. As part of his responsibilities in Business Development, Thomas Sager has been involved in multiple licensing, M&A opportunities and deals.
Partner at BHV Partners / Startup Builders since 2018.
Recent News
December 03, 2024
Contera Pharma Welcomes New Board Members to Drive Strategic Growth
[Hørsholm, Denmark – December 03, 2024] – Contera Pharma A/S, a clinical-stage biotech company pioneering treatments for neurological disorders, is proud to…
Read more
November 28, 2024
Contera Pharma announces first patient dosed in Phase 1b trial of CP-012, a novel therapy to treat nocturnal immobility and morning akinesia in Parkinson’s disease
Contera Pharma A/S, a clinical-stage biotech company pioneering innovative treatments for neurological disorders, has announced the dosing of the first patient in…
Read more
Contact us
Contera Pharma
Contera Pharma A/S
Venlighedsvej 4
2970 Hørsholm
Denmark
Thomas Sager, CEO
info@conterapharma.com